Unibest

Pharmaceutical intermediates

Pacritinib Intermediates

5 pharmaceutical intermediates for Pacritinib. Indication: Primary or Secondary Myelofibrosis.

提交项目All intermediates

About Pacritinib

Originator
S*BIO Pte Ltd
Indication
Primary or Secondary Myelofibrosis
Approved Date
02/28/2022
NCE Patent
02/28/2027
DS/DP
05/05/2028

Available intermediates

5 intermediates currently listed for Pacritinib. Request specifications, documentation or a quotation for any item below.

Pacritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
[3-(2-Chloro-pyrimidin-4-yl)-phenyl]-methanol859517-90-1//
2-(2-chloroethoxy)-5-nitrobenzaldehyde110837-53-1//
2-((allyloxy)Methyl)-1-(2-chl oroethoxy)-4-nitrob937273-31-9//
4-(3-(allyloxymethyl)phenyl)-2-chloropyrimidine937273-29-5//
3-(allyloxymethyl)-4-(2-(pyrrolidin-1-yl)ethoxy)benzenamine937273-33-1//

Other programs under P

PalbociclibParecoxib sodiumParicalcitolPaxlovidPazopanib HydrochloridePeficitinib HydrobromidePemafibratePeramivir

Building toward Pacritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →